Deena R. Altman
A5081285167- Antimicrobial Resistance in Staphylococcus
- COVID-19 Clinical Research Studies
- Bacterial Identification and Susceptibility Testing
- SARS-CoV-2 and COVID-19 Research
- Sepsis Diagnosis and Treatment
- Bacterial biofilms and quorum sensing
- Mycobacterium research and diagnosis
- Streptococcal Infections and Treatments
- Long-Term Effects of COVID-19
- Clostridium difficile and Clostridium perfringens research
- COVID-19 and healthcare impacts
- Poxvirus research and outbreaks
- Bacillus and Francisella bacterial research
- Intensive Care Unit Cognitive Disorders
- Antibiotic Resistance in Bacteria
- Nosocomial Infections in ICU
- Monoclonal and Polyclonal Antibodies Research
- Cystic Fibrosis Research Advances
- Herpesvirus Infections and Treatments
- Infective Endocarditis Diagnosis and Management
- Biochemical and Structural Characterization
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Bacteriophages and microbial interactions
- COVID-19 epidemiological studies
- Gut microbiota and health
Icahn School of Medicine at Mount Sinai
2016-2025
Benaroya Research Institute
2022
Mount Sinai Hospital
2020-2021
Office of Infectious Diseases
2010
SARS-CoV-2 antibodies persist As the number of daily COVID-19 cases continues to mount worldwide, nature humoral immune response severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort more than 30,000 infected individuals with mild moderate symptoms determine robustness and longevity anti–SARS-CoV-2 antibody response. They found that neutralizing titers against spike protein persisted for at least 5 months after infection. Although...
<h3>Importance</h3> The US is currently an epicenter of the coronavirus disease 2019 (COVID-19) pandemic, yet few national data are available on patient characteristics, treatment, and outcomes critical illness from COVID-19. <h3>Objectives</h3> To assess factors associated with death to examine interhospital variation in treatment for patients <h3>Design, Setting, Participants</h3> This multicenter cohort study assessed 2215 adults laboratory-confirmed COVID-19 who were admitted intensive...
Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract inflammatory cytokine release syndrome severe COVID-19 illness.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human with few effective treatments1. Convalescent plasma, donated persons who have recovered from COVID-19, the acellular component of blood that contains antibodies, including those specifically recognize SARS-CoV-2. These when transfused into patients infected SARS-CoV-2, are thought to exert an antiviral effect, suppressing virus replication before mounted their own...
Blighted Gotham Deaths caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in New York City (NYC) during the spring of 2020 have vastly exceeded those reported China and many other countries. What were early events that led to such a outbreak? Gonzalez-Reiche et al. sampled some patients seeking assistance February March at Mount Sinai Health System. Phylogenetic analysis virus sequences these people, who drawn from across NYC, showed had been independently introduced...
Hypercoagulability may be a key mechanism of death in patients with coronavirus disease 2019 (COVID-19).
Abstract SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Questions regarding the robustness, functionality longevity of antibody response to virus remain unanswered. Here we report that vast majority individuals mild-to-moderate COVID-19 experience robust IgG responses against viral spike protein, based on dataset 19,860 screened at Mount Sinai Health System in New York City. We also show titers are stable for least period approximating three months,...
Background Since December 2019, Coronavirus Disease 2019 (COVID-19) has become a global pandemic, causing mass morbidity and mortality. Prior studies in other respiratory infections suggest that convalescent plasma transfusion may offer benefit to some patients. Here, the outcomes of thirty-nine hospitalized patients with severe life-threatening COVID-19 who received were compared against cohort retrospectively matched controls. Methods Plasma recipients selected based on supplemental oxygen...
Clinical Implications•We describe 3 patients with X-linked agammaglobulinemia coronavirus disease 2019 who failed supportive treatment but recovered after receiving convalescent plasma. •We The (COVID-19) pandemic has presented a global challenge. pathogenesis of severe acute respiratory syndrome 2 (SARS-CoV-2) infection is complex, and effective therapy currently lacking. Convalescent plasma transfusion safe under investigation for effectiveness.1Bloch E.M. Shoham S. Casadevall A. Sachais...
Previous viral pandemics have shown that secondary bacterial infections result in higher morbidity and mortality, with Staphylococcus aureus being the primary causative pathogen. The impact of S. bacteremia on mortality patients infected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unknown.This was a retrospective observational case series disease 2019 (COVID-19) who developed across New York City hospitals. end point to describe 14-day 30-day hospital rates COVID-19...
The epidemic community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) USA300 lineage has recently become a leading cause of hospital-associated bloodstream infections (BSIs). Here, we leveraged this recent introduction into hospitals and the limited genetic variation across isolates to identify mutations that contribute its success in new environment. We found BSI exhibit altered virulence regulation. Using comparative genomics delineate genes involved phenotype, discovered...
Staphylococcus aureus organisms vary in the function of staphylococcal virulence regulator gene agr. To test for a relationship between agr and transmission S. aureus, we determined prevalence genetic basis dysfunction among nosocomial methicillin-resistant (MRSA) an area MRSA endemicity. Identical inactivating mutations were not detected epidemiologically unlinked clones within or hospitals. Additionally, most mutants had single mutations, indicating that they short lived. Collectively,...
The past two decades have witnessed an alarming expansion of staphylococcal disease caused by community-acquired methicillin-resistant
ABSTRACT New York City (NYC) has emerged as one of the epicenters current SARS-CoV2 pandemic. To identify early events underlying rapid spread virus in NYC metropolitan area, we sequenced causing COVID19 patients seeking care at Mount Sinai Health System. Phylogenetic analysis 84 distinct genomes indicates multiple, independent but isolated introductions mainly from Europe and other parts United States. Moreover, find evidence for community transmission suggested by clusters related viruses...
Rationale: Variation in hospital mortality has been described for coronavirus disease (COVID-19), but the factors that explain these differences remain unclear. Objective: Our objective was to use a large, nationally representative data set of critically ill adults with COVID-19 determine which variability. Methods: In this multicenter cohort study, we examined hospitalized ICUs at 70 U.S. hospitals between March and June 2020. The primary outcome 28-day mortality. We patient-level...
The current study identified bacterial factors that may improve management of methicillin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia. Isolates were obtained from 386 patients enrolled in a randomized, controlled antibiotic efficacy. screened for production virulence and vancomycin susceptibility. After adjustment host such as severity illness treatment modality, cytotoxic activity was strongly inversely associated with mortality; however, it had no effect on clinical cure....
Therapy for bacteremia caused by Staphylococcus aureus is often ineffective, even when treatment conditions are optimal according to experimental protocols. Adapted subclones, such as those bearing mutations that attenuate agr -mediated virulence activation, associated with persistent infection and patient mortality.
In 2022 the World Health Organization declared a Public Emergency for an outbreak of mpox, zoonotic Orthopoxvirus (OPV) affecting at least 104 nonendemic locations worldwide. Serologic detection mpox infection is problematic, however, due to considerable antigenic and serologic cross-reactivity among OPVs smallpox-vaccinated individuals. this report, we developed high-throughput multiplex microsphere immunoassay using combination mpox-specific peptides cross-reactive OPV proteins that...